174 related articles for article (PubMed ID: 10194135)
1. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.
Shvidel L; Shtalrid M; Bassous L; Klepfish A; Vorst E; Berrebi A
Leuk Lymphoma; 1999 Mar; 33(1-2):169-79. PubMed ID: 10194135
[TBL] [Abstract][Full Text] [Related]
2. Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia.
Crisostomo RH; Fernandez JA; Caceres W
Leuk Res; 2007 May; 31(5):699-701. PubMed ID: 16997373
[TBL] [Abstract][Full Text] [Related]
3. Prolymphocytic leukemia: diagnosis and treatment. A case report.
Akin C; Hansen P; Janckila A
J Ky Med Assoc; 1997 Nov; 95(11):465-7. PubMed ID: 9392933
[TBL] [Abstract][Full Text] [Related]
4. [Prolymphocytic leukemia: the therapeutic strategy].
Fava S; De Paoli A; Grimi E; Luoni M; Tocci A; Tosi A; Cassi E
Recenti Prog Med; 1994 Oct; 85(10):496-501. PubMed ID: 7809465
[TBL] [Abstract][Full Text] [Related]
5. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia.
Saven A; Lee T; Schlutz M; Jacobs A; Ellison D; Longmire R; Piro L
J Clin Oncol; 1997 Jan; 15(1):37-43. PubMed ID: 8996122
[TBL] [Abstract][Full Text] [Related]
6. ProMACE day 1/MOPP day 8 chemotherapy for prolymphocytic leukemia: a case report of prolonged survival.
Yuen BH; Godwin JE
Am J Hematol; 1994 Jul; 46(3):230-3. PubMed ID: 8192154
[TBL] [Abstract][Full Text] [Related]
7. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.
Garand R; Goasguen J; Brizard A; Buisine J; Charpentier A; Claisse JF; Duchayne E; Lagrange M; Segonds C; Troussard X; Flandrin G
Br J Haematol; 1998 Nov; 103(2):488-94. PubMed ID: 9827924
[TBL] [Abstract][Full Text] [Related]
8. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
9. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Döhner H; Ho AD; Thaler J; Stryckmans P; Sonneveld P; de Witte T; Lechner K; Lauria F; Bödewadt-Radzun S; Suciu S
J Natl Cancer Inst; 1993 Apr; 85(8):658-62. PubMed ID: 8468724
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival in two cases of T-prolymphocytic leukemias with complex hypodiploid chromosomal abnormalities.
Yokohama A; Karasawa M; Takada S; Matsushima T; Murakami H; Miyao S; Sato S; Naruse T
J Med; 2000; 31(3-4):183-94. PubMed ID: 11280450
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
Murase K; Matsunaga T; Sato T; Kuribayashi K; Kogawa K; Kawano Y; Okamoto T; Takayama T; Watanabe H; Niitsu Y; Hirayama Y
Int J Clin Oncol; 2003 Dec; 8(6):391-4. PubMed ID: 14663643
[TBL] [Abstract][Full Text] [Related]
12. Current treatment options in prolymphocytic leukemia.
Robak T; Robak P
Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
[TBL] [Abstract][Full Text] [Related]
13. B-CLL in PLL transformation associated with hypercalcemia.
Lerner D; Esteves C; De Oliveira MS
Leuk Lymphoma; 1994 Jan; 12(3-4):321-5. PubMed ID: 8167564
[TBL] [Abstract][Full Text] [Related]
14. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms.
Hercher C; Robain M; Davi F; Garand R; Flandrin G; Valensi F; Vandeputte H; Albert A; Maynadie M; Troussard X; Simon GH; Lespinasse J; Portefaix G; Merle-Beral H;
Leuk Lymphoma; 2001; 42(5):981-7. PubMed ID: 11697653
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
16. Infiltration of the thyroid gland by T-cell prolymphocytic leukemia.
Fujiwara K; Fukuhara T; Kitano H; Okazaki T
Thyroid; 2014 Aug; 24(8):1314-8. PubMed ID: 24762052
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
18. B-Prolymphocytic leukemia: a case study.
Roberts JC; Roberts GH
Clin Lab Sci; 2001; 14(4):233-7. PubMed ID: 11760820
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
20. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
